methyl 3-(3,4-dichlorophenyl)-3-butenoate | 191673-76-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: methyl 3-(3,4-dichlorophenyl)-3-butenoate
• 英文别名: methyl 3-(3,4-dichlorophenyl)but-3-enoate
• CAS: 191673-76-4
• 化学式: C₁₁H₁₀Cl₂O₂
• 分子量: 245.105
• InChiKey: ZRXNSCKARNQGCD-UHFFFAOYSA-N

物化性质

• 沸点：
  334.2±37.0 °C(Predicted)
• 密度：
  1.252±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  methyl 3-(3,4-dichlorophenyl)-3-butenoate 在 吡啶 、 盐酸 、 4-二甲氨基吡啶 、 sodium hydroxide 、 lithium aluminium tetrahydride 、 AD-mix-β 、 lithium perchlorate 、 三乙胺 、 三苯基膦 、 偶氮二甲酸二乙酯 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 、 乙腈 、 叔丁醇 为溶剂， 反应 42.5h， 生成 (R)-2-(2-(3,4-dichlorophenyl)morpholin-2-yl)ethanol
  参考文献：
  名称：

  An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin-2-yl]ethanols, key intermediates of tachykinin receptor antagonist

  摘要：

  We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2[(2R)-arylmorpholin-2-yl]ethanols 1a-d, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asymmetric dihydroxylation of 4a-d was employed to introduce the required absolute stereochemistry, and cyclization of 7a-d was accomplished by the Mitsunobu reaction. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00336-x
• 作为产物：
  描述：

  3,4-二氯溴苯 在 bis-triphenylphosphine-palladium(II) chloride 、 硫酸 、 碘 、 magnesium 、 zinc(II) chloride 作用下， 反应 2.0h， 生成 methyl 3-(3,4-dichlorophenyl)-3-butenoate
  参考文献：
  名称：

  An efficient synthesis of enantiomerically pure 2-[(2R)-arylmorpholin-2-yl]ethanols, key intermediates of tachykinin receptor antagonist

  摘要：

  We report herein an efficient and practical synthetic method for the preparation of enantiomerically pure 2[(2R)-arylmorpholin-2-yl]ethanols 1a-d, key intermediates of tachykinin receptor antagonist. Sharpless catalytic asymmetric dihydroxylation of 4a-d was employed to introduce the required absolute stereochemistry, and cyclization of 7a-d was accomplished by the Mitsunobu reaction. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(98)00336-x

文献信息

• Method for treating an inflammatory disease
  申请人：Sankyo Company, Limited

  公开号：US06448247B1

  公开（公告）日：2002-09-10

  Compounds of the formula and quaternary ammonium ions thereof, wherein R1 and R2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C1-C4 alkylene or C2-C4 alkenylene; D is oxygen or sulfur; E is C2-C6 alkylene, C1-C6 haloalkylene, C3-C6 cycloalkane-1,1-diyl or C3-C6-cycloalkane-1,1-diylmethyl; G is C1-C4 alkylene or C2-C4 alkenylene; and L is —NR3 or —C(R4)(R5), wherein R3 is a carbocyclic aryl or an aromatic heterocyclic; R4 is hydrogen, carbocyclic aryl or aromatic heterocyclic; R5 is —COR6, C1-C6 alkyl, C1-C6 alkoxy, amino, or acylamino, wherein R6 is C1-C6 alkyl or C1-C6 alkoxy, or R4 and R5 together with the carbon atom to which they are attached represent a C5-C10 cycloalkyl or a C5-C10 heterocyclic. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK1 and NK2 receptors.

  该分子式的化合物及其季铵盐，其中R1和R2相同或不同，为碳环芳基或芳香族杂环；A为亚甲基，羰基或磺酰基；B为单键，C1-C4烷基或C2-C4烯基；D为氧或硫；E为C2-C6烷基，C1-C6卤代烷基，C3-C6环烷-1,1-二基或C3-C6-环烷-1,1-二基甲基；G为C1-C4烷基或C2-C4烯基；L为—NR3或—C（R4）（R5），其中R3为碳环芳基或芳香族杂环；R4为氢，碳环芳基或芳香族杂环；R5为—COR6，C1-C6烷基，C1-C6烷氧基，氨基或酰胺基，其中R6为C1-C6烷基或C1-C6烷氧基，或R4和R5与它们连接的碳原子一起代表C5-C10环烷基或C5-C10杂环。这些化合物具有缓激肽受体拮抗活性，并对NK1和NK2受体均表现出活性。
• Heterocyclic compounds having tachykinin receptor antagonist activity
  申请人：Sankyo Company, Limited

  公开号：US06159967A1

  公开（公告）日：2000-12-12

  Compounds of the formula and quaternary ammonium ions thereof, wherein R.sup.1 and R.sup.2 are the same or different and are carbocyclic aryl or aromatic heterocyclic; A is methylene, carbonyl or sulfonyl; B is a single bond, C.sub.1 -C.sub.4 alkylene or C.sub.2 -C.sub.4, alkenylene; D is oxygen; E is C.sub.2 alkylene; G is C.sub.1 -C.sub.4 alkylene or C.sub.2 -C.sub.4 alkenylene; and L is --C(R.sup.4)(R.sup.5), wherein R.sup.4 and R.sup.5 together with the carbon atom to which they are attached represent a C.sub.5 -C.sub.10 cycloalkyl or a C.sub.5 -C.sub.10 heterocyclic. Especially preferred are compounds wherein L represents ##STR1## wherein J is a C.sub.1 -C.sub.6 alkylene; Ar is a ring carbocyclic or aromatic heterocyclic and S*.fwdarw.O is a sulfoxide in which the sulfur atom is in the 5-configuration. The compounds have tachykinin receptor antagonist activity and exhibit an activity against both the NK.sub.1 and NK.sub.2 receptors.

  该化合物的配方及其季铵离子，其中R.sup.1和R.sup.2相同或不同，是碳环芳基或芳香杂环；A是亚甲基，羰基或磺酰基；B是单键，C.sub.1-C.sub.4烷基或C.sub.2-C.sub.4烯基；D是氧；E是C.sub.2烷基；G是C.sub.1-C.sub.4烷基或C.sub.2-C.sub.4烯基；L是--C(R.sup.4)(R.sup.5)，其中R.sup.4和R.sup.5与它们附着的碳原子一起表示C.sub.5-C.sub.10环烷基或C.sub.5-C.sub.10杂环。特别喜欢的化合物是其中L表示##STR1##其中J是C.sub.1-C.sub.6烷基；Ar是环状碳环或芳香杂环，S*.fwdarw.O是一种亚砜，其中硫原子处于5位构型。这些化合物具有速激肽受体拮抗剂活性，并对NK.sub.1和NK.sub.2受体均有活性。
• SALTS OF OPTICALLY ACTIVE SULFOXIDE DERIVATIVE
  申请人：Sankyo Company Limited

  公开号：EP0987269A1

  公开（公告）日：2000-03-22

  The below-described compound has good oral adsorption and exhibits markedly excellent antagonistic action against both NK1 receptors and NK2 receptors. Hydrochloride or fumarate of 1-2-[(2R)-(3,4-dichlorophenyl)-4-(3,4,5-trimethoxybenzoyl)morpholin-2-yl]ethyl}spiro[benzo(c)thiophene-1(3H),4'-piperidin]-(2S)-oxide.

  下述化合物具有良好的口服吸附性，对 NK1 受体和 NK2 受体都有明显的出色拮抗作用。 1-2-[(2R)-(3,4-二氯苯基)-4-(3,4,5-三甲氧基苯甲酰基)吗啉-2-基]乙基}螺[苯并(c)噻吩-1(3H),4'-哌啶]-(2S)-氧化物的盐酸盐或富马酸盐。
• Azaheterocyclic compounds having tachykinin receptor antagonist activity; Nk1 and NK2
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0776893B1

  公开（公告）日：2002-02-27
• US6159967A
  申请人：——

  公开号：US6159967A

  公开（公告）日：2000-12-12